Tekturna (aliskiren) / PDL, Novartis  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
NCT01454583: Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany

Completed
N/A
15337
Europe
Aliskiren, Rasilez, ACE-I/ARB, No RAS-inhibition
Stiftung Institut fuer Herzinfarktforschung, Novartis Pharmaceuticals
Arterial Hypertension
10/09
07/12
NCT01393860: Real-world Aliskiren Use in Diabetic Patients

Completed
N/A
200
US
Novartis
Diabetes, Hypertension
06/11
 
NCT01165983: The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

Completed
N/A
124
US
Placebo, Aliskiren, Trade name: Tekturna
Beth Israel Deaconess Medical Center, Novartis Pharmaceuticals
Diabetes Type 2
01/12
 
NCT01425242 / 2011-000538-12: Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension

Terminated
N/A
3
Europe
Aliskiren, Rasilez, Amlodipine, Norvasc
Amsterdam UMC, location VUmc, Novartis
Hypertension, Abdominal Aortic Aneurysm
12/13
12/13
NCT01420068 / 2011-004411-22: 52-104 Week Off-therapy Second Extension to Study CSPP100A2365

Completed
N/A
106
US, Europe, RoW
SPP100
Noden Pharma
Hypertension
08/17
08/17

Download Options